News
A multi-site clinical trial led by researchers at the University of Kentucky Center on Drug and Alcohol Research (CDAR) has demonstrated the effectiveness of CAM2038, a potentially transformative buprenorphine therapy for moderate-to-severe opioid use disorders.
Even with the assistance of detoxification and rehabilitation programs, 80 percent of people attempting recovery from opioid addiction will relapse.
The firm grip of opioid addiction on a person鈥檚 life necessitates sustainable therapeutic approaches proven effective through scientific trials and evidence.